Occlusive arterial disease, including coronary heart disease (CHD) and peripheral arterial
disease (PAD), is the main cause of death, with an annual mortality incidence predicted to …

Current clinical treatment strategies for the bypassing of small diameter (< 6 mm) blood
vessels in the management of cardiovascular disease frequently fail due to a lack of suitable …

Due to the lack of efficacy of synthetic vascular substitutes in the replacement of small-
caliber arteries, vascular tissue engineering (VTE) has emerged as a promising solution to …

Cardiovascular disease is the leading cause of death worldwide, with this trend predicted to
continue for the foreseeable future. Common disorders are associated with the stenosis or …

This article reviews the present state of small-diameter vascular substitution, the
mechanisms of graft failure and the ongoing matters of graft design, with particular attention …

Vascular tissue engineering has made prodigious progress in recent years by converging
multidisciplinary approaches. Latest technological advancements foster the development of …

Vascular disease results in the decreased utility and decreased availability of autologus
vascular tissue for small diameter (< 6 mm) vessel replacements. While synthetic polymer …

Cardiovascular disease serves as the leading cause of death worldwide, with stenosis,
occlusion, or severe dysfunction of blood vessels being its pathophysiological mechanism …

Tissue-engineered vascular grafts (TEVGs) have emerged as a new choice for substitution
of damaged blood vessels. A passage of a new blood vessel can be regenerated through …

Introduction: Conventional synthetic vascular grafts are limited by the inability to remodel, as
well as issues of patency at smaller diameters. Tissue-engineered vascular grafts (TEVGs) …